NEW YORK, December 16, 2020 — EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated computational approach to humanizing antibody sequences.
Antibody humanizing is a process that entails replacing as much of the rabbit antibody sequence with human antibody sequence, to the point that the final antibody is more human than rabbit. This process is essential to the drug development process – without humanization, the human immune system would not tolerate a rabbit antibody.
Results are expected by Q2 2021.